SEC Comment Letter for Rein Therapeutics, Inc. (RNTX) (CIK 0001420565) (RNTX) — Aug 15, 2018
Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)
Date: Aug. 15, 2018 · CIK: 0001420565 · Accession: 0000000000-18-025320
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226650
Letter
August 15, 2018 John P. Longenecker Chief Executive Officer Aileron Therapeutics, Inc. 281 Albany Street Cambridge, MA 02139 Re:Aileron Therapeutics, Inc. Registration Statement on Form S-3 Filed August 7, 2018 File No. 333-226650 Dear Mr. Longenecker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Stuart M. Falber, Esq.
Show Raw Text
August 15, 2018
John P. Longenecker
Chief Executive Officer
Aileron Therapeutics, Inc.
281 Albany Street
Cambridge, MA 02139
Re:Aileron Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 7, 2018
File No. 333-226650
Dear Mr. Longenecker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Stuart M. Falber, Esq.